ABL1 and acute lymphoblastic leukemia: The other pre-TKI studies did not demonstrate any advantage of AHSCT over chemotherapy in this population.22,28 Conversely, several recently published studies have shown that AHSCT preceding by TKI and chemotherapy may result in similar outcome to that achieved by allogeneic HSCT.29,30 Based on the recent reports it seems reasonable to offer AHSCT for Ph+ ALL patients without a family donor and no detectable BCR-ABL transcript at transplant.